Govt backs permanent pharmacy UTI prescribing — the evidence gaps matter

Uncomplicated urinary tract infections are one of the most common reasons a woman contacts a GP. They are painful, disruptive, and usually straightforward — a few days of nitrofurantoin or trimethoprim, and most resolve. The access friction is real: a telehealth consultation takes time and costs a co-payment, and the delay can turn a manageable infection into a miserable week.

Which is why Tasmania’s pharmacist UTI prescribing pilot was always going to be politically appealing. And why the evaluation recommending it become permanent deserves more scrutiny than the headline suggests.

According to AusDoc, pharmacists conducted 6,534 UTI consultations under the pilot, supplying antibiotics in 91% of cases. Average consultation: 10 minutes. Approximately 85% of Tasmanian community pharmacies participated. The evaluation was conducted by Tasmania’s own Department of Health and has now recommended the program be made permanent.

On the surface, that sounds like a functioning program. The problem is what the evaluation did not measure.

The 120-out-of-6,534 problem

Patient outcome feedback was collected from 120 consultations. That is 1.8% of the consultations the program actually conducted.

Without meaningful patient-outcome data across the full program, the evaluation cannot tell you:

• How many patients had symptoms that resolved within 48-72 hours
• How many had recurrent infections within 4 weeks
• How many had an STI or complicated infection that was missed at the pharmacy triage
• What antibiotic was selected and whether it aligned with local resistance patterns — which the national AURA surveillance system tracks in detail
• Whether any cases of early pyelonephritis were delayed in reaching clinical care

The evaluation was conducted internally. A program evaluating its own performance, with 1.8% outcome data, recommending its own permanence, is not independent evidence.

The AusDoc report specifically flags the “glaring holes in evidence” — language that belongs in a critique, not in the summary of a study recommending policy entrenchment. When evidence is described as having glaring holes, the appropriate policy response is usually to fill them before expanding. Not to proceed and review later.

Both-and: access and assessment are genuinely both real

This is not a clean story about pharmacy access being good or bad.

The access benefit is real. UTIs disproportionately affect women, and barriers to prompt GP access — rural geography, appointment availability, co-payment cost — have genuine clinical consequences. Delayed treatment of even an uncomplicated UTI produces real suffering, and there is nothing medically optimal about a woman in a remote Tasmanian town waiting two days for a telehealth slot when she has a classic presentation.

Pharmacists declining to supply when patients present with risk factors — fever, flank pain, pregnancy, diabetes, immunosuppression, structural abnormalities — also suggests the triage is working in straightforward high-risk exclusions.

And: a 10-minute pharmacy consultation is not a clinical assessment. The conditions that present as uncomplicated UTI include early pyelonephritis, chlamydia, bacterial vaginosis, and interstitial cystitis. A 45-year-old woman with recurrent UTI symptoms may have a structural issue, an as-yet undiagnosed type 2 diabetes, or an antibiotic resistance pattern that requires urine culture to detect. Ninety-one per cent antibiotic supply in 10-minute consultations, without culture data, is a pattern worth auditing.

The RACGP and GP sector have raised antibiotic stewardship concerns about this type of expansion for exactly this reason. Resistance is a population-level outcome, invisible in any single patient encounter but accumulating in the aggregate. It is the kind of harm that does not show up in a 120-patient feedback sample.

2 cents

The policy question and the clinical question run on separate tracks here.

For patients: if this program extends to other states, it will mean faster access to treatment for uncomplicated UTIs, which is a net access benefit for most women presenting with classic symptoms — dysuria, frequency, no systemic features. The clinical flag is: if your symptoms include fever, back or loin pain, nausea, vomiting, or you have had more than two UTIs in six months — a GP consultation matters, regardless of what the pharmacy pathway offers.

For the broader policy moment: the evidence gaps are serious enough that endorsing permanent expansion without addressing them is a risk to antibiotic stewardship and to the patients whose complicated infection gets missed. The fact that the evaluation was self-administered by the programme operator, with 1.8% outcome data, recommending its own continuation, is not a foundation for confident national expansion. It is a foundation for a properly independent evaluation.

Tasmania’s program will almost certainly become permanent. Other states will likely follow. That trajectory makes getting the evidence base right now more important, not less — because decisions made at the pilot stage become defaults at the national scale.

Verdict: maybe — the access case is real, but independent outcome data must precede confident endorsement of permanent expansion.

---

Sources cited

1. Govt evaluation backs permanent pharmacy prescribing for UTIs despite glaring holes in evidence — AusDoc
2. AURA — antimicrobial use and resistance in Australia, ACSQHC